Reason for request
Reassessment
Clinical Benefit
| Insufficient |
The Committee deems that the clinical benefit of BLENREP (belantamab mafodotin) 100 mg, powder for solution for dilution for infusion, is insufficient in the MA indication to justify public funding. |
Clinical Added Value
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
tC4wepSV74mZpGtC
